A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.

Many use cases potentially suit AliveCor’s smartphone-based ECG device, which delivers medical-grade cardiac data to consumers, patients and doctors on demand. Artificial intelligence is just one element of the technology offering, says the company’s VP, EMEA Stefan Holzer.

System interoperability and building trust in AI capabilities are central to the strategic collaboration and organic growth plans at GE HealthCare, according to US and Canada regional president and CEO Catherine Estrampes, who spoke to In Vivo as the company released the findings of a major survey of clinicians and patients on future healthcare system needs.

BridgeBio and US FDA agreed on a path to accelerated approval for BB-418, a Phase III oral candidate for a subset of limb-girdle MD patients. If successful, it would bring BridgeBio’s third product to market.